Evidence mapPaperPMID 37374016Full record

ReviewLife (Basel, Switzerland)2023

Diabetes Mellitus after SARS-CoV-2 Infection: An Epidemiological Review.

Irena Ilic, Milena Ilic

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Irena IlicFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-5347-3264
Milena IlicDepartment of Epidemiology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0003-3229-4990
University of Belgrade · RSUniversity of Kragujevac · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus (DM) is among the major global public health issues. According to recent projections, a continued rise in DM prevalence is expected in the following decades. The research has shown that DM is associated with poorer outcomes of coronavirus disease 2019 (COVID-19). However, there is growing evidence suggesting that COVID-19 is associated with new-onset DM type 1 and type 2. This review aims to summarize the current knowledge about the new onset of DM following COVID-19. All identified studies were longitudinal, and they have predominantly shown a significantly increased risk for new-onset DM (both type 1 and type 2) following a SARS-CoV-2 infection. Increased risk of poorer COVID-19 outcomes (mechanical ventilation, death) was noted in persons with new-onset DM following SARS-CoV-2 infection. Studies investigating risk factors for new-onset DM in COVID-19 patients showed that severe disease, age, ethnicity, ventilation, and smoking habits were associated with DM occurrence. The information summarized in this review presents a valuable source of evidence for healthcare policymakers and healthcare workers in the effort of planning prevention measures for new-onset DM after SARS-CoV-2 infection and the timely identification and appropriate treatment of patients with COVID-19 who could be at greater risk for new-onset DM.

Indexed as

diabetes mellitusepidemiologyrisk factorsSARS-CoV-2

Identifiers

PMID37374016
PMCPMC10301286
OpenAlexW4378086708

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.